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ABSTRACT 31 
Endothelial barrier (EB) breaching is a frequent event during inflammation, and it is followed 32 
by the rapid recovery of microvascular integrity. The molecular mechanisms of EB recovery 33 
are poorly understood. Triggering of MHC molecules by migrating T-cells is a minimal signal 34 
capable of inducing endothelial contraction and transient microvascular leakage. Using this 35 
model, we show that EB recovery requires a CD31 receptor-induced, robust glycolytic 36 
response sustaining junction re-annealing. Mechanistically, this response involves src-37 
homology phosphatase activation leading to Akt-mediated nuclear exclusion of FoxO1 and 38 
concomitant β-catenin translocation to the nucleus, collectively leading to cMyc transcription. 39 
CD31 signals also sustain mitochondrial respiration, however this pathway does not contribute 40 
to junction remodeling. We further show that pathologic microvascular leakage in CD31-41 
deficient mice can be corrected by enhancing the glycolytic flux via pharmacological Akt or 42 
AMPK activation, thus providing a molecular platform for the therapeutic control of EB 43 
response. 44 
 45 
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INTRODUCTION  (4936) 54 
Physiological hyper-permeability is a typical microvasculature inflammatory response of, which 55 
facilitates diffusion of essential blood-borne immunoregulatory and pro-inflammatory mediators 56 
into extravascular tissue. Microvascular leakage results from a tightly regulated process induced 57 
by a wide range of inflammatory mediators. This event leads to phosphorylation and endocytosis 58 
of junctional vascular endothelial cadherin (VE-cadherin) complex and EC actomyosin 59 
contractility1,2. Endothelial contraction can open junctions via a number of molecular mediators1,2. 60 
Microvascular leakage can be accompanied by leukocyte extravasation3,4. For example, we have 61 
shown that Major Histocompatibility Complex (MHC) molecule-ligation by migrating T 62 
lymphocytes or antibodies induces transient microvascular leakage to facilitate T-cell 63 
extravasation5. Mechanistically, EC MHC-class-I engagement induces a rapid translocation of 64 
RhoA to the cell membrane associated with F-actin stress fiber formation and cytoskeleton 65 
reorganization leading to cell contraction6. This effect is physiologically relevant to human disease, 66 
as capillary-leak syndrome is a key feature of vascularized allografts rejection7-9. 67 
Following leukocyte crossing, microvascular integrity quickly recovers through re-annealing of 68 
inter-endothelial junctions, but the molecular basis of this process is poorly defined. Most 69 
mechanistic studies have been carried out in-vitro10. In-vivo studies have used EC-contraction 70 
mediators such as thrombin and LPS which also affect other cellular functions and cells, 71 
particularly immune cells11,12 thus adding confounding factors which prevent the mechanistic 72 
study of EBF recovery.   73 
 74 
Inter-endothelial CD31-homophilic interactions are required to recover vascular integrity following 75 
MHC-stimulation by migrating T-lymphocytes5. CD31 is a member of the immunoglobulin gene 76 
superfamily expressed at high density at the lateral borders of endothelial cells13. CD31 77 
cytoplasmic tail contains two immunoreceptor-tyrosine-based-inhibitory-motifs (ITIM), which upon 78 
activation, specifically recruit src-homology 2 tyrosine phosphatases SHP-2 and SHP-1. Although 79 
CD31-deficient mice do not spontaneously develop vascular leakage at steady state, CD31-80 
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deficincy has been associated with excessive vascular leakage following endothelial contraction 81 
induced by histamine14, thrombin15 and LPS-induced endotoxemia16-17. Importantly, loss CD31 82 
expression by EC leads to uncontrolled T-cell extravasation in inflammatory conditions18,19. While 83 
this evidence points to a non-redundant role of CD31 in the recovery of endothelial continuity 84 
after barrier breach by stimuli inducing endothelial contraction, the molecular mechanisms are to-85 
date unclear. 86 
We have investigated the molecular mechanism of EBF recovery in response to endothelial 87 
contraction and junction release-inducing stimuli using in-vitro and in-vivo models of MHC-88 
induced vascular leakage in the context of inter-endothelial CD31 interactions. We show that the 89 
re-establishment of microvascular integrity is dependent on a CD31-induced glycolytic response, 90 
which sustains coordinated cytoskeletal remodeling and junctional reassembly. 91 
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RESULTS 92 
 93 
CD31 is required for endothelial barrier recovery. 94 
To investigate the molecular mechanisms involved in the recovery of endothelial barrier function 95 
(EBF) we conducted preliminary studies to monitor the kinetics of endothelial permeability 96 
induced by MHC-class-I molecule signals (via antibody-ligation) in the presence or absence of 97 
CD31 co-engagement in confluent, WT and cd31−/− EC monolayers.  Treatment with IFN-γ was 98 
used to enhance MHC and ICAM-1 molecule expression, which is low in cultured endothelium20, 99 
as we have previously described 5. As expected, antibody-triggering of MHC led to a quick and 100 
similar reduction in trans endothelial electrical resistance (TEER) by both WT and cd31−/− 101 
endothelium (Supplementary Fig. 1a). However, while permeability of WT endothelium returned 102 
to baseline levels within 6 h, resistance of CD31-deficient endothelium remained significantly 103 
lower for up to 24 h after MHC-stimulation. TEER was not significantly affected by ICAM-1 Ab-104 
mediated stimulation in conditions capable to induce Erk phosphorylation either in the presence 105 
or absence of CD31 expression, (Supplementary Fig. 1b). MHC-triggering did not induce EC 106 
death (Supplementary Fig. 1c).  107 
As endothelial contractility is associated with F-actin polymerization and stress fiber formation 21, 108 
we further analyzed EC cytoskeletal rearrangements following MHC-triggering with or without 109 
CD31 ligation.   Sub-confluent EC monolayers were used in these experiments to allow 110 
assessing the contribution of CD31 signals ‘in isolation’, i.e. via antibody activation, on actin 111 
polymerization. MHC-ligation led to the formation of polarized bundles of F-actin stress fibers and 112 
further separation from adjacent EC (Fig. 1a-b), a feature of EC contraction. The sparsity of the 113 
MHC-stimulated EC on the image is likely to reflect the strength of cell contraction, possibly even 114 
leading to cell detachment, as the EC were seeded in equal numbers. This was confirmed by 115 
experiments showing a similar actin configuration in MHC-stimulated CD31-deficient EC 116 
(Supplementary Fig. 1d), While CD31 triggering on its own did not elicit any effect, co-ligation 117 
with MHC molecules significantly increased F-actin polymerization above the levels induced by 118 
MHC-signals, which was however associated with the cortical actin cytoskeleton and 119 
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accompanied by intercellular attachment, suggesting that CD31 is required for efficient 120 
anchorage of actin fibers to the intercellular junctions during EC contraction. ICAM-1 ligation 121 
induced a slight increase in actin polymerization without endothelial contraction (c-d) and was not 122 
affected by co-delivery of CD31-mediated signals. Experiments designed to define the molecular 123 
mechanisms of sustained permeability of MHC-stimulated cd31−/− endothelium revealed 124 
enhanced Erk and RhoA small GTPase activation in CD31-deficient but not WT EC (Fig. 1e-f). 125 
This pathway has been previously shown to induce endothelial contraction22. Immunoprecipitation 126 
studies in confluent EC confirmed that CD31 becomes phosphorylated upon MHC- but not ICAM-127 
1 molecule stimulation, and this leads to the recruitment of the Src Homology Phosphatase 2 128 
(SHP2), a key mediator of CD31 signals (Fig. 1g). 129 
To validate the functional consequences of these observations, we tested the effect of signals on 130 
vascular barrier function in-vivo. First, we used a selective minimal signal – i.e. MHC-antibody 131 
ligation - to avoid confounding effects related to the engagement of other endothelial receptors by 132 
T-cells. In addition, systemic administration of the antibody allowed comparing EBFin multiple 133 
organs, and estimate the specific effect of MHC-signals in the absence of other inflammatory 134 
signals. In these experiments IFN-γ was not administered to avoid confounding effects. A non-135 
complement fixing anti-MHC-class-I antibody was mixed with a secondary antibody and injected 136 
intravenously in WT and CD31-deficient mice. An anti-ICAM-1 antibody plus specific secondary 137 
antibody was also administered as a control. After 3 and 6 hours, mice were injected with Evans 138 
Blue i.v. and tracer extravasation was measured. Vascular permeability was significantly 139 
increased after 6 hours in the lung, liver and kidney of cd31-/-, but not WT animals, which received 140 
anti-MHC antibody (Fig. 1h). Interestingly, no increase in the permeability of the brain vasculature 141 
was observed in either WT or cd31-/- mice, likely due to low MHC expression typical of brain 142 
endothelium 23,24. No effects were observed following ICAM1 stimulation (Supplementary Fig. 1e). 143 
Systemic MHC-stimulation elicited a vascular leakage similar to that of histamine (Supplementary 144 
Fig. 1f), a stimulus well known to induce EC contraction with amplified severity in cd31-/- mice17.  145 
We subsequently assessed the effect of MHC-triggering by T-cells both in-vitro and in-vivo. 146 
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In-vitro, allogeneic (H2-D) T-cells were generated by in-vitro stimulation with DC obtained from 147 
WT donors (H2-B) and subsequently seeded on IFN-γ-treated (48 hours) WT or cd31-/- EC 148 
monolayers grown on 0.2μm pore transwells. TEER increased only in WT EC monolayers for the 149 
first 6 hours, while it remained low in the cd31-/- ECs (Fig. 1i). The absence of TEER decrease in 150 
this system compared to direct MHC-ligation is that adhering T-cells also contribute to higher 151 
TEER. In-vivo, we induced systemic T-cell:MHC cognate interactions by i.v. injection of 152 
staphylococcal enterotoxin A (SEA). After i.p. injection of IFN-γ 48 hours earlier, SEA 153 
administration induced greater vascular leakage in CD31-deficient mice in all organs analyzed 154 
except the brain (Fig. 1j). IFN-γ alone also increased vascular permeability in some organs, but 155 
this was minimal compared to SEA administration (Supplementary Fig. 1g).  156 
Integrity of intercellular junctions is a major determinant of permeability of the endothelium, and 157 
de-phosphorylation of VE-cadherin-catenin complexes in adherens junctions mediate both 158 
anchorage and mechanical coupling of the cytoskeleton of adjacent EC including during 159 
leukocyte extravasation1,2, 25-26.  160 
We therefore analyzed β-catenin phosphorylation in response to MHC- and ICAM-1-mediated 161 
signals by CD31-expressing or –deficient EC. Both MHC- and ICAM-1-ligation led to a modest 162 
increase in β-catenin phosphorylation at tyrosine 654 (Fig. 2a), which was substantially increased 163 
in the absence of CD31-mediated interactions during MHC- but not ICAM-1-triggering, indicating 164 
that CD31 modulates MHC-induced β-catenin phosphorylation as confirmed by wide-field 165 
fluorescence microscopy (Fig. 2b-c). Accordingly, VE-cadherin phosphorylation increased 166 
substantially in MHC-activated CD31-deficient EC (Fig. 2d-e).  167 
The causative role of CD31-mediated signals on vascular integrity was confirmed by lentiviral 168 
transduction of cd31-/- ECs with wild-type CD31-gene constructs (KOCD31WT) or an empty plasmid 169 
(KOploc.1), or two CD31-gene constructs with mutation with loss-of-function amino acid 170 
substitutions Y663F and Y686F in the ITIMs (KOCD31Y663F, KOCD31Y686F ECs) (Supplementary Fig. 171 
2a-b). Reconstitution with an intact CD31 gene rescued the ability of cd31-/- EC to recover barrier 172 
function upon MHC-ligation (Fig. 2 f-g).  This was also achieved by KOCD31Y663F but not KOCD31Y686F 173 
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EC, suggesting that phosphorylation at amino-acid residue tyrosine 686, known to be essential for 174 
SHP2 recruitment by CD31 is instrumental for its ability to maintain barrier function27. Similar to 175 
cd31-/-, KOCD31Y686F EC underwent VE-cadherin and β-catenin phosphorylation (Supplementary 176 
Fig. 2 c-d). Conversely, tyrosine-663 but not -686 was instrumental for CD31 intracellular 177 
trafficking28, suggesting that the two ITIMs may differentially contribute to distinct CD31 functions. 178 
The role of CD31 was further confirmed in experiments in which CD31 and/or MHC were 179 
antibody-ligated on sparsely seeded WT EC which showed that Akt activation only occurred in 180 
the presence of CD31 ligation (Supplementary Fig. 2 e-f), ruling out that MHC-mediated signals 181 
on their own induce this signaling pathway. 182 
 183 
CD31-induced metabolic reprogramming regulates EBF response. 184 
The observations above do not explain the intense membrane-associated cytoskeleton 185 
reorganization and EC contraction induced by MHC and CD31 co-engagement. Although Src-186 
induced phosphorylation of VE-cadherin prevents the binding of β-catenin, this is not sufficient to 187 
increase endothelial permeability 29,30. 188 
EC metabolism has recently emerged as an important regulator of endothelial function 31,32,33. 189 
WT EC permeability following MHC-stimulation for 3 hours (i.e. when it would normally return to 190 
baseline) was dramatically increased by inhibition of glycolysis with the glucose analogue 2-191 
deoxyglucose (2-DG), indicating that recovery of junction stability upon MHC-triggering might 192 
depend on a robust glycolytic response (Fig. 3a). 193 
We therefore investigated the effect of MHC- and CD31-mediated signals on EC metabolism. To 194 
avoid activation of metabolic pathways due to EC proliferation or migration these experiments 195 
were performed using confluent EC monolayers. Expression of the ubiquitous glucose transporter 196 
Glut1 and uptake of the glucose-analogue 6-[N-7-nitrobemz-2-oxa-1,3-diazol-4-amino]-2-197 
deoxyglucose (6-NBDG), which accumulates in the cytoplasm in its fluorescent form, were 198 
significantly increased in CD31-competent, but not -deficient EC following --stimulation (Fig. 3b-d, 199 
Supplementary Fig. 3a). Importantly, 2-DG pre-treatment of EC abrogated 6-NBDG uptake 200 
irrespective of CD31 expression, suggesting a positive feed-back loop of glycolysis itself on 201 
 10
glucose uptake. We further observed that cd31-/- EC failed to redistribute Glut1 upon MHC-202 
stimulation, suggesting a defect in Glut1 recycling to the cell membrane (Supplementary Fig. 3b). 203 
Accordingly, ATP levels in response to MHC-triggering were significantly reduced in CD31-204 
deficient EC (Fig. 3e). When stimulated with insulin, however, ATP levels were increased in 205 
CD31-deficient EC compared to WT EC. As insulin is a powerful inducer of glycolysis34, not 206 
supplemented in EC culture medium, CD31-deficient EC are capable to engage the glycolytic 207 
pathway in response to insulin, but not MHC-stimulation. 208 
To differentiate the effects of MHC-stimulation on aerobic glycolysis from other glucose-209 
dependent functions (such as protein glycosylation), we measured lactate production by MHC-210 
activated WT and cd31-/- EC. The reduced glycolytic ability of cd31-/- EC was confirmed by 211 
measurement of extracellular acidification rate (ECAR). The glycolytic flux in resting, confluent 212 
EC was significantly decreased in CD31-deficient EC, suggesting that inter-endothelial CD31 213 
interactions support baseline glycolysis in resting endothelium (Fig. 3f). MHC-stimulation of WT, 214 
but not cd31-/- EC, resulted in significantly enhanced ECAR (Fig. 3g-h). A glycolysis stress test 215 
confirmed that cd31-/- EC display an impaired basal glycolytic response, reserve and maximal 216 
response (Fig. 3i-k), independently of MHC-triggering. We further analyzed the effect of 217 
reconstitution of lentivirus-transduced cd31-/- EC with either CD31WT, CD31ploc.1, CD31Y663F and 218 
CD31Y686F gene constructs on the glycolytic response to MHC-triggering and confirmed that 219 
tyrosine 686 is required for CD31 signals to elicit this metabolic response (Supplementary Fig. 3c) 220 
The oxygen consumption rate (OCR), a measure of mitochondrial respiration, was severely 221 
compromised in both resting and MHC-activated cd31-/- EC (Fig. 4 a-b). OCR was not affected by 222 
MHC-ligation in WT EC, while both maximal respiration and spare capacity were significantly 223 
enhanced in CD31-deficient EC (c-d), suggesting that in the absence of CD31 signals, EC 224 
engage mitochondrial respiration to meet energy demands. We therefore assessed mitochondria 225 
number, shape and cristae morphology MHC-activated WT and cd31-/- EC. No differences in the 226 
number of mitochondria in resting EC were observed (Fig. 4 e-g). In contrast, MHC-stimulated, 227 
CD31-deficient EC displayed increased mitochondria size (f) and numbers (g), with increased 228 
cristae width compared to their WT counterpart (h). The overall increase in mitochondrial mass 229 
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by MHC-stimulated cd31-/- EC was confirmed by flow cytometry (i). Mitochondrial function this 230 
was found to be severely reduced in cd31-/- EC (Fig. 4j), which nevertheless increased it in 231 
response to MHC-stimulation. 232 
 233 
It has been shown that T-cells that preferentially utilize FAO, maintain fused mitochondria 35,36. 234 
We therefore compared WT and CD31-deficient EC ability to oxidize glucose, glutamine and fatty 235 
acids (FAO). As shown in Supplementary Fig. 2a, glucose oxidation did not significantly differ in 236 
unstimulated WT and cd31-/- EC. However, while glucose oxidation was increased in WT EC in 237 
response to MHC-signals, this pathway was impaired in CD31-deficient EC (Supplementary Fig. 238 
3d). Glutamine oxidation, in contrast, was utilized more by resting CD31-deficient EC, which were 239 
however unable to increase it following MHC-stimulation (Supplementary Fig. 3e). FAO was 240 
significantly enhanced by MHC-stimulated CD31-deficient but not WT EC (Supplementary Fig. 3f). 241 
Accordingly, transcription of the mitochondrial enzyme carnitine palmitoyltransferase 1A (cpt1a), 242 
essential for FAO, was enhanced by MHC-stimulation in CD31-deficient endothelium 243 
(Supplementary Fig. 3g). 244 
 245 
The data obtained with CD31Y686F (Fig. 2f-g) implicate SHP-2 activation in CD31-mediated barrier 246 
recovery along with previous observations37. We therefore examined the effect of pharmacologic 247 
inhibition of SHP-2 on the metabolic response of WT EC to MHC-stimuli. In steady-state 248 
conditions, EC monolayer permeability was increased by pre-treatment with a selective SHP1/2 249 
small-molecule-inhibitor, without induction of cell death (Fig. 5a-b). The glycolytic response to 250 
MHC-triggering was abrogated in confluent monolayers of CD31-expressing EC following SHP 251 
inhibition (c-d). An even greater effect was observed when CD31-deficient EC were analyzed (e-252 
f). In these experiments, the glycolytic pathway was impaired also in unstimulated EC, suggesting 253 
that additional SHP phosphatases might contribute to sustain glycolysis in quiescent endothelium. 254 
Miitochondrial respiration was not affected by SHP-inhibition in quiescent WT or CD31-deficient 255 
EC, suggesting that the defect in OXPHOS observed in cd31-/- EC is not caused by lack of SHP 256 
activation.  SHP inhibition did not modify OCR in MHC-stimulated WT EC (g-h), while it was 257 
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further increased in cd31-/- endothelium (i-j). Thus, SHP activation is required for glycolysis while 258 
it does not affect mitochondrial respiration. 259 
 260 
CD31 signals inhibit FoxO1 nuclear-translocation. 261 
Cellular ability to activate glycolysis depends on availability of glycolytic enzymes31,33.  We 262 
therefore investigated expression of enzymes of the glycolytic pathway known to be functional in 263 
the endothelium before and after MHC-stimulation of WT and CD31-deficient EC.  264 
MHC-stimulation of WT EC did not modify expression of Enolase 1 and 2 and Phosphoglycerate 265 
mutase, but led to upregulation of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 266 
(PFKFB3, Fig. 6a-b,), a key regulator of glycolysis during EC migration 31, and Aldolase A, known 267 
to bind to actin and regulate cytoskeletal reorganization 38. Enzymes levels were substantially 268 
diminished in cd31-/- endothelium, irrespective of MHC-stimulation, with the exception of elevated 269 
expression of PFKFB3, also in unstimulated CD31-deficient EC. PFKFB3 synthesize fructose-270 
2,6-bisphosphate (F2,6P2), an activator of 6-phosphofructo-1-kinase (PFK-1), which converts 271 
fructose-6-phosphate (F6P) to fructose-1,6-biphosphate (F1,6P2), which might reflect a 272 
compensatory mechanism. 273 
Reduced Aldolase expression by CD31-deficient EC reflected lack of increased transcription 274 
upon MHC-triggering, suggesting that CD31-signals promote a transcriptional program (Fig. 6c). 275 
Further, in WT, but not cd31-/- EC, aldolase localized in areas of actin remodeling, including the 276 
lateral borders, suggesting a role for this enzyme in the maintenance of actin anchorage to 277 
intercellular junctions (Supplementary Fig. 4a).   278 
The forkhead box O (FoxO) transcription factors control fundamental cellular processes, including 279 
metabolism. FoxO1 is a negative regulator of vascular growth32 Depending on its phosphorylation 280 
status, FoxO1 shuttles between nucleus and cytoplasm. When localized to the nucleus, FoxO1 281 
modulates gene transcription by binding to response sequences located in the promoter. We 282 
have previously shown that CD31-induced AKT-mediated phosphorylation inhibits FoxOs by 283 
preventing their nuclear localization39.  284 
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SHP2-mediated CD31-signals imaintain Akt activation26, hence we confirmed that Akt 285 
phosphorylation was induced in CD31-expressing, but not -deficient EC (6d). 286 
We subsequently analyzed FoxO1 localization following MHC-stimulation in WT and cd31-/- EC. 287 
Immunofluorescence studies revealed enriched FoxO1-signal in endothelial nuclei of MHC-288 
stimulated cd31-/- EC, but not in WT EC (6e-f).  289 
In EC, FoxO1 downregulates glycolytic enzyme expression by suppressing cMyc-induced 290 
transcription32. We show that cMyc expression was enhanced by MHC-stimulation in WT, but not 291 
cd31-/- EC  (Fig. 6g). Notably, cMyc controls aldolase gene transcription40,41.  292 
Treatment of WT EC with the SHP-inhibitor led to nuclear translocation of FoxO1 (Fig. 6h-i and 293 
Supplementary Figure 5a), Conversely, Akt activation reduced FoxO1 nuclear translocation. 294 
SHP-inhibition reduced cMyc transcription in MHC-stimulated WT EC, while AKT activation 295 
restored Myc transcription in MHC-activated, CD31-deficient EC (Fig. 6j and Supplementary Fig. 296 
5b-c).  297 
 298 
β-catenin contributes to metabolic responses to MHC-signals. 299 
In addition to stabilizing adherens junctions, β-catenin, a member of the Wnt signalling cascade, 300 
delivers signals to the nucleus, influencing metabolic transcriptional programs42. De-301 
phosphorylated β-catenin can translocate into the nucleus where it promotes transcription of 302 
target genes, including cMyc42. Phosphorylation of β-catenin leads to ubiquitination and 303 
degradation via the proteasome43. CD31-signals stabilize β-catenin by preventing its 304 
phosphorylation induced by MHC-engagement (see Fig. 2b-c).  To investigate whether β-catenin 305 
participates to metabolic reprogramming of EC following MHC-stimulation, localization of β-306 
catenin in MHC-stimulated EC was investigated. MHC-ligation of WT EC enhanced β-catenin 307 
nuclear translocation leading to a concomitant increase of cMyc expression in the nucleus (Fig. 308 
7a-c). This event did not occur in CD31-deficient EC, indicating a causative role for CD31-309 
generated signals in the nuclear shuttling of β-catenin upon MHC-triggering. In CD31-deficient 310 
EC, nuclear localization of β-catenin and increased cMyc expression was restored following 311 
pharmacological Akt activation. 312 
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We then we analysed the transcription of both cMyc and its target aldolase upon MHC-stimulation 313 
in both WT and CD31-deficient ECs. cMyc transcription was increased as early as 30 minutes 314 
after stimulation, peaked at 2 hours and returned to baseline by 4 hours (Fig. 7d). Accordingly, 315 
aldolase transcription was also increased by 30 minutes, but continued to remain elevated up to 4 316 
hours after stimulation (Fig. 7e). Stimulation of cd31-/- EC did not induce transcription of any of 317 
the genes analysed.  318 
 319 
Inducing CD31-independent glycolysis restores EC barrier. 320 
We next investigated whether this pathway is essential to the recovery of EC barrier function 321 
following MHC-stimulation by directly activating this metabolic response independently of CD31-322 
signals.   323 
First, as Akt activation is instrumental to couple CD31 signals with metabolic reprogramming of 324 
EC towards glycolysis, we assessed the effect of pharmacological Akt activation on the glycolytic 325 
flux in MHC-activated CD31-deficient endothelial cells. As shown in Fig. 8a and Supplementary 326 
Fig. 6a-c, direct Akt activation could bypass the lack of CD31 signals and enhance cd31-/- EC 327 
glycolysis in response to MHC-ligation.  328 
 329 
Although via different pathways, cMyc and AMP kinase (AMPK) influence similar cellular 330 
metabolic pathways including glycolysis and oxphos44,45,46,47. Besides promoting glycolysis 48, 331 
AMPK has been implicated in angiogenesis following ischemia 49 and can induce phosphorylation 332 
and degradation of FoxO1 in EC 50. CD31-deficient EC exposed to the AMPK-activator Metformin 333 
50 recovered their glycolytic response to MHC-ligation (Fig. 8b and Supplementary Fig. 6a-c). 334 
Further, treatment with Metformin restored FoxO1 nuclear exclusion in MHC-stimulated, CD31-335 
deficient EC (Fig. 8c-d). Neither Akt- nor AMPK-activation modified mitochondrial respiration 336 
(Supplementary Fig. 6d-e).  337 
We then assessed the impact of Akt- or AMPK-activation on the barrier response in CD31-338 
deficient endothelium. Both Akt- and AMPK-activation restored TEER in cd31-/- EC following 339 
MHC-stimulation (Fig. 8e) without affecting permeability of unstimulated WR or cd31-/- EC 340 
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(Supplementary Fig. 6f). Consistently, pathological vascular leakage induced by systemic MHC-341 
ligation in cd31-/- mice was corrected by the administration of either an Akt activator or Metformin 342 
(Fig. 8f).  343 
 344 
To confirm the ability of AMPK-induced glycolysis in recovering EBF independently of CD31-345 
signals and exclude potential off-target effects of Metformin and CD31-deficiency in leukocytes13, 346 
we generated bone marrow (BM) chimeras in which WT BM was administered to sublethally 347 
irradiated cd31-/- recipients (CD31 selectively-expressed by EC). Some mice were treated with 348 
the high affinity AMPK-selective small molecule allosteric activator 99151. Treatment with AMPK 349 
activator restored cd31-/- EC glycolytic response to MHC-stimulation (Fig. 8g-h), TEER recovery 350 
in MHC-stimulated cd31-/- EC in-vitro  (Fig. 8i) as well as barrier response following systemic 351 
MHC-stimulation in cd31-/- mice (Fig. 8j).  352 
Finally, we investigated the physiopathological relevance of our findings both in mice and humans. 353 
To confirm that a pathway initiated by CD31-signals and inducing glycolysis is physiologically 354 
relevant to the recovery of microvascular integrity following MHC-triggering by migrating T 355 
lymphocytes, we assessed the EBF and histopathological features of rejection of male-derived 356 
CD31-/- skin grafts by WT female recipients. Re-establishment of endothelial continuity between 357 
recipient and graft vasculature in HY-mismatched skin graft combinations is established by 14 358 
days after grafting, while T-cell dependent rejection becomes clinically evident at day 28-35 and it 359 
is accelerated in CD31-deficient skin39,52. 360 
As shown in Fig. 8k-l, CD31-deficient, male-derived skin was grafted onto female WT littermates 361 
and, as a control, WT females received CD31-deficent or WT, female-derived skin. Some mice 362 
were treated with Metformin (+Met), or vehicle alone. Two weeks later, mice were injected with 363 
Evans Blue i.v. and tracer extravasation in the grafts was measured. As shown in Fig. 8k, CD31-364 
deficient male-derived skin grafts displayed significantly higher vascular leakage compared to 365 
WT-derived grafts. Importantly, female-derived skin graft vasculature appeared functionally intact 366 
irrespective of CD31 expression, confirming that the leakage was caused by MHC:HY complexes 367 
ligation by allospecific T-cells. Metformin-treatment significantly reduced tracer extravasation in 368 
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CD31-deficient male-derived skin grafts. Comparison of histological features revealed substantial, 369 
protein-rich papillary dermal edema, - as demonstrated by the large quantity of eosinophil 370 
material deposed between cells, indicative of severe microvascular leakage - in CD31-deficient 371 
compared to WT male-derived skin grafted onto female WT recipients (Fig. 8l). Edema in CD31-372 
deficient grafts was reduced by treatment with Metformin. WT and CD31-deficient, female-373 
derived skin graft did not display pathological features. 374 
In humans, we correlated the effect of loss of CD31 expression and vascular leakage by 375 
comparing soluble CD31 (sCD31) molecules in the serum of patients with sepsis and septic 376 
shock (Supplementary Table 1 and 2, respectively)53. CD31-deficient mice have severely reduced 377 
survival to LPS-induced endotoxic shock, associated with enhanced vascular permeability16-17. In 378 
humans, CD31 is shed from endothelium activated by strong pro-inflammatory stimuli54,55, and 379 
sCD31 levels have been correlated with sepsis severity56. As shown in Supplementary Figure 6i, 380 
serum levels of sCD31 were significantly elevated in patients with septic shock compared with 381 
those of sepsis patients, consistent with the hypothesis that loss of CD31 expression by the 382 
endothelium undermines its ability to preserve vascular integrity. 383 
 384 
385 
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DISCUSSION 386 
 387 
By modeling endothelial cell contraction and vascular leakage induced by MHC-signals, we show 388 
that recovery of endothelial integrity involves a complex integration of Akt-dependent molecular 389 
events, including nuclear exclusion of FoxO1, β-catenin stabilization and nuclear translocation, 390 
and induction of cMyc expression, leading to engagement of the glycolytic flux (summarized in 391 
Fig. 9). These events likely reflect the requirement for ATP-sustained actin remodeling to re-392 
establish junctional anchorage to cytoskeletal components. The dramatic metabolic impairment 393 
due to loss of CD31 expression selectively applies endothelial adaptation in response to stimuli 394 
that induce EC contraction and barrier breach. Previous studies have demonstrated that 395 
endothelial migration and proliferation – which also involve intense cytoskeleton reorganization - 396 
are dependent on a similar metabolic response31,32. Other receptors on CD31-deficient EC can 397 
induce metabolic reprogramming – as vascular functions such as angiogenesis and endothelial 398 
proliferation, which are highly dependent on glycolysis, appear to be normal in these mice. 399 
 400 
Our observations suggest that MHC-signals per se can induce stress fiber formation 401 
independently of CD31-induced signals, possibly via a pathway involving RhoA and Erk 402 
activation22, but that the maintenance of association of the cytoskeleton with junctions and 403 
junctional integrity require CD31 phosphorylation.  404 
We further show that SHP-2 activation by CD31 signals is instrumental to the recovery of 405 
junctional stability, through the initiation of Akt-dependent metabolic reprogramming required for 406 
optimal cytoskeletal reorganization and junction re-assembly. The role of CD31 in the 407 
maintenance of junctional stability has been attributed to mechanical bridging of EC and junction 408 
stabilization by de-phosphorylation of β-catenin and VE-cadherin57. Our observations rather 409 
support a prominent role for this receptor in the initiation of a signaling pathway culminating in the 410 
production of energy to sustain actin remodeling and junction annealing.  411 
 412 
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Akt activation is central to this function of the CD31 receptor. The two major mediators, which 413 
define the contribution of Akt signalling in metabolic reprogramming leading to junction 414 
stabilization, are β-catenin and FoxO1. FoxO1 is prevented from translocating to the nucleus after 415 
phosphorylation by Akt58. Concomitantly, Akt inactivates GSK-3β, which sequester β-catenin in 416 
the cytoplasm59 leading to β-catenin stabilization and nuclear translocation60. Ultimately, CD31 417 
maintains the efficiency of the glycolytic machinery in EC by promoting β-catenin-mediated c-418 
Myctranscription, which in turn promotes expression of the glucose transporter Glut-1 and 419 
Aldolase A 40. 420 
 421 
Interestingly, in the absence of CD31 signals, PFKFB3 protein expression by EC is increased, 422 
suggesting that the regulation of this enzyme transcription is cMyc independent. PFKFB3 gene 423 
expression has been shown to be inhibited by shear stress through Kruppel-like factor-2 (KLF2) 424 
in EC61, and was enhanced by HIF Serum Response Factor in various tumor cell lines61, but has 425 
never been associated with cMyc-induced transcription. 426 
 427 
Unlike what was observed in human EC transduced with a gain-of-function FoxO1 allele 428 
rendering FoxO1 constitutively nuclear32, our data indicate that enhanced FoxO1 nuclear 429 
translocation leads to increased oxidative metabolism, probably fueled by fatty acid oxidation 430 
(FAO). The reason for this discrepancy is at present unclear, but could be related to phosphatase 431 
targets other than the FoxO1 pathway in our system. It is worth noting that the identity of 432 
phosphatase enzyme(s), which dephosphorylate FoxO1 is at present unknown. In addition, the 433 
pattern of FoxO phosphorylation can differentially affect its activities 62  and it is possible that 434 
different phosphorylation patterns might reflect a stimulus-specific modulation which leads to 435 
stimulus specific-effects.  436 
 437 
An unexpected feature of CD31-deficient EC is their severely compromised mitochondrial 438 
respiration associated with a large number of enlarged mitochondria. It has been suggested that 439 
in response to stressors, mitochondria become enlarged decreasing the rate of oxygen 440 
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consumption, leading to decreases in the rate of ROS production and ATP63. Relevant to the 441 
focus of this study, metformin-induced AMPK activation restores the EBF and glycolysis without 442 
affecting mitochondrial respiration, suggesting that oxidative phosphorylation is not required for 443 
restoring endothelial continuity after contraction and barrier breach. In addition, SHP inhibition 444 
does not affect OCR by WT ECs, thus ruling out a role for this CD31-signaling mediator. 445 
Understanding the molecular mechanism and the functional consequences of the defective 446 
oxphos in CD31-deficient EC will require further investigations. Of note, oxidative phosphorylation 447 
is plays a role in sustaining endothelial cell division64  and attenuation of vascular development 448 
has been observed in CD31-deficient mice65. 449 
We further show that, unlike MHC-stimulation, exposure to insulin results in an increased ATP 450 
levels in CD31-deficient EC, suggesting that CD31-deficient EC are capable to engage the 451 
glycolytic pathway in response to insulin receptor, but not MHC-stimulation. This also implies that 452 
the metabolic alterations of CD31-deficient EC might become apparent only as a result of 453 
selected signals, such as MHC-triggering or histamine, and that insulin receptor signals are not 454 
affected by CD31 activity. The enhanced ATP production in response to insulin by CD31-deficient 455 
EC compared to WT also indicates that compensatory mechanisms are in place to compensate 456 
for the severe deficiency in mitochondrial respiration in these cells.  457 
 458 
The contribution of CD31 signals in the maintenance of barrier integrity has long been 459 
contentious57.  In inflammatory conditions, the impact of CD31 activity on junction stability during 460 
leukocyte migration appears to be stimulus-specific66. Similarly, endothelial contraction is not 461 
required for IL-1β-induced leukocyte migration67. Genetic deletion of the actin nucleation-462 
promoting factor cortactin in mice is associated with reduced neutrophil recruitment but increased 463 
vascular permeability in-vivo68, thus demonstrating that transendothelial migration and vascular 464 
leakage can be associated, but not necessarily coupled. In agreement with these reports, our 465 
data show that ICAM-1-mediated signals do not result in endothelial contraction and temporary 466 
vascular leakage, while suggesting that metabolic adaptation by EC is paramount to the barrier 467 
response to severe ‘breaching’ signals, such as those induced by histamine, thrombin and MHC-468 
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ligation. Physiologically, this would reflect a prominent role of CD31 signaling during inflammatory 469 
conditions characterized by high endothelial contractility (histamine, MHC-triggering) leading to 470 
potential vascular damage.  471 
CD31-induced metabolic responses appear to be largely dependent on a specific transcriptional 472 
program. While our fluxometry studies show that an increased glycolytic rate immediately follows 473 
MHC-stimulation of WT EC and MHC-stimulation rapidly induces translocation to Glut1 to the 474 
endothelial surface, full re-establishment of endothelial integrity in-vivo (see Fig. 1 h and i) 475 
requires approximately 2-3 hours. Such a prolonged energy requirement is likely to require, as we 476 
show, a rapid and sustained transcriptional reprogramming leading to increased expression of 477 
glycolysis-promoting genes such as cMyc and aldolase.    478 
 479 
In further support of the requirement of endothelial metabolic adaptation in inflammatory 480 
conditions characterized by severe barrier breach, treatment with Metformin has been known to 481 
promote favorable outcome in sepsis, a condition characterized by systemic endothelial leakage 482 
69-71. Similarly, inhibition of Abl family kinases, which phosphorylate β-catenin, attenuates vascular 483 
leakage induced by thrombin, histamine, vascular endothelial growth factor (VEGF), 484 
lipopolysaccharide (LPS), and oxidative stress72-76. The present study provides a molecular basis 485 
for these clinical observations. Thus, in-depth knowledge of endothelial metabolic adaptation in 486 
health and disease, and of the endothelial receptors regulating metabolic reprogramming might 487 
provide novel targets for the prevention and therapy of diseases characterized by endothelial 488 
dysfunction. 489 
 490 
  491 
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METHODS  492 
 493 
Mice. cd31−/−77  and wild type (WT) male and female mice were bred in house in SPF conditions 494 
and used at the age of 8–10 weeks. All in-vivo experiments were conducted with strict adherence 495 
to the Home Office guidelines (PPL P71E91C8E) following approval by the Queen Mary 496 
University of London Ethics committee. The number of animals required to obtain statistical 497 
significance was estimated based on similar studies previously performed. Animals were not 498 
randomized, and no blinding was done. 499 
 500 
Patients.  A total of 13 patients admitted to ITU (Campus Biomedico Hospital, Rome, Italy) in 501 
November-December 2018 were divided into two groups: the sepsis group (n=7) and the septic 502 
shock group (n=6), diagnosed based on the criteria proposed at the American College of Chest 503 
Physicians/Society of Critical Care Medicine Consensus Conference in 1992. Informed written 504 
consent was obtained from all subjects or patients’ surrogates. This study was approved by the 505 
local Research Ethics Committee (Prot. 28.18TS ComEt CBM). Serum samples were used for 506 
the sCAM analysis. The tubes were left for 20 min to allow for clotting and centrifuged at 1560 9 g 507 
for 10 min, at 4 °C. Serum was stored at -80 °C until analysis using a Human CD31 ELISA Kit. 508 
 509 
Regents. The following antibodies were used in this study: Rabbit-anti-mouse-Phospho-Akt 510 
(Ser473) Antibody (Cell signalling, AB329825) 1:200 dilution, Rabbit-anti-mouse-Akt (pan) 511 
(C67E7) Antibody (Cell signaling AB915783) 1:200 dilution, Rabbit-anti-mouse- P-ERK1/2 512 
Antibody (Cell signalling, AB331646) 1:100 dilution, Rabbit-anti-mouse ERK1/2 Antibody (Santa 513 
Cruz,  Sc292838) 1:100 dilution, Mouse-anti-mouse P-tyrosine (PY20) Antibody (Santa Cruz, Sc 514 
508) 1:200 dilution, Rabbit-anti-mouse SHP2 Antibody (Abcam ab131541) 1:200 dilution, Rabbit-515 
anti-mouse Ubiquitin Antibody (Abcam ab7780) 1:200 dilution, Goat anti-actin-I19 Antibody (Santa 516 
Cruz Biotechnology, Sc1616) 1:200 dilution, Rabbit-anti-mouse PFKFB3 (D7H4Q) Antibody (Cell 517 
signalling, 13123) 1:200 dilution, Rabbit-anti-mouse Enolase-2 (D20H2)  Antibody (Cell signaling,  518 
AB11178392) 1:200 dilution, Rabbit-anti-mouse Enolase-1 Antibody  (Cell signalling, 519 
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AB2246524) 1:200 dilution, Rabbit-anti-mouse Aldolase A  Antibody (Cell signalling, AB2226674) 520 
1:200 dilution, Rabbit-anti-mouse PGAM1  Antibody (Cell signalling,12098) 1:200 dilution, Anti-521 
rabbit IgG, HRP-linked Antibody (Cell signalling, AB2099233) 1:200 dilution, Rabbit-anti-522 
mouse rac1/cdc42 Antibody (Cell signalling,  AB10612265) 1:200 dilution, Rabbit-anti-mouse PE-523 
conjugated anti- CD31 Antibody (Thermofisher AB465631) 1:200 dilution,  Rat IgG2a K Isotype 524 
Control Antibody (Thermofisher  AB470104), Rabbit-anti-mouse p-β-catenin (phospho Y654) 525 
Antibody (Abcam ab59430) 1:200 dilution, Rabbit-anti-mouse VE-cadherin (phospho Y685) 526 
Antibody (Abcam AB10971838) 1:200 dilution, Rabbit-anti-mouse VE-cadherin Antibody (Abcam 527 
ab205336) 1:200 dilution. 528 
 529 
Rabbit-anti-mouse β-Catenin  Antibody (Abcam AB11127855) 1:200 dilution ,Rabbit-anti-mouse 530 
Anti-PFKFB3 Antibody  (Abcam AB181861) 1:200 dilution, Rabbit-anti-mouse Anti-beta Actin 531 
Antibody (Abcam AB16039) 0.5 µg/mL dilution, Rabbit-anti-mouse c-Myc Antibody (Abcam 532 
AB10858578), Alexa Fluor® 555 goat anti-mouse Ig Antibody (Life Technology AB2563179), and 533 
FITC Donkey anti-rabbit IgG (minimal x-reactivity) Antibody (Life Technology AB893531), Rabbit-534 
anti-mouse FoxO1 Antibody (Abcam AB2106495) 1:200 dilution, Mouse-anti-mouse anti-Glut1-PE 535 
Antibody (Novusbio, NB110-39113PE) 1:200 dilution, Rabbit-anti-mouse anti-Erk1/2 (H72) 536 
Antibody (Santa Cruz , SC292838) 1:200 dilution, Rabbit-anti-mouse Glut1 Antibody AF647 537 
(Novus Bio, NB110-39113AF647) 1:100 dilution, Rabbit-anti-mouse Aldolase antibody (Abcam, 538 
ab169544) 1:200 dilution, tetramethyl rhodamine B isothiocyanate-phalloidin (Sigma , P1951)  50 539 
units/assay dilution.  540 
Mouse-anti-mouse H-2Ld/H-2Db (MHC-class-I) Antibody (Biolegend , 114502), Rat–anti-mouse 541 
IgG, (Biolegend, 553445), (Blocking) rat anti-mouse CD31 clone 390 (eBioscience , AB10060377), 542 
(Stimulate) rabbit anti-mouse CD31 (Abcam, ab2836), Goat–anti-rabbit Ig Antibody, (Agrisera , 543 
AS10 665), (cross-linkage) Mouse-anti-mouse ICAM-1 (Abcam,  ab2213) were used to stimulate 544 
MHC molecules on the endothelium. 545 
Other reagents include the SHP1/2 inhibitor CAS 56990-57-9, (Bioscience , NSC 87877) , Akt 546 
activator (Tocris , SC79), Metformin (Sigma-Aldrich , 317240), Evans blue (Sigma-Aldrich, E2129-547 
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10G), 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (Sigma-Aldrich, 269913-1G), 548 
Tetramethyl rhodamine B isothiocyanate–conjugated phalloidin (Sigma-Aldrich, P1951), ProLong 549 
Gold Antifade (LifeTechnologies,P36930), Type IV Collagenase (Sigma-Aldrich, C5138), FBS 550 
(Seralab, A210009), Dulbecco's Modified Eagle media (DMEM, Gibco 41966-052), glutamine 551 
( Gibco250-30),  2-Mercaptoethanol (2-ME) (Gibco 31350-010), sodium pyruvate ( Gibco 11360-552 
039), HEPES (Gibco  15630-056), non-essential amino acids (Gibco 11140-050),trypsin/EDTA 553 
(Gibco T4049), murine IFN-γ (PeproTech 315-05) , glucose free T-cell medium (Gibco, 11879-554 
020), 6-NBDG (Life Technologies, N23106), RNeasy Mini Kit (50) (Qiagen, 74104), iQ™ SYBR® 555 
Green Supermix (Biorad, 1708880) , High-Capacity RNA-to-cDNA™ Kit (Life Technologies, 556 
4387406), MitoTracker™ Green FM (Thermofisher Scientific, M7514) ,MitoTracker™ Red 557 
CMXRos (Thermofisher Scientific ,M7512), Uranyl acetate (VWR 102092-282), Histamine (Sigma, 558 
59964), Corning® HTS Transwell®-24 well permeable supports (Fisher Scientific Ltd, 10228861), 559 
Formamide (Sigma, F9037), Paraformaldehyde 95% (Sigma, 158127), Staphylococcal 560 
enterotoxin A from Staphylococcus aureus (Sigma, S9399), 2-Deoxy-D-glucose (Sigma, D8375), 561 
Trypsin-EDTA (0.25%) phenol red (Thermo Fisher 25200056), ECL Western Blotting Detection 562 
Reagent (Amersham, RPN2209), Fujifilm Super RX film (Fuji, RF12), Foxp3 / Transcription Factor 563 
Staining Buffer Set (Thermo Fisher, 00-523-00), Poly-D-Lysin (Gibco™, A3890401), Insulin 564 
(Sigma, 11061-68-0).    565 
 566 
Isolation and culture of primary microvascular endothelial cells  567 
Microvascular endothelial cells were isolated from murine lungs20 and cultured in (DMEM 568 
ThermoFisher 41966), supplemented with 10% FCS). When confluent, cells were detached with 569 
trypsin/EDTA (Gibco, T4049) and passaged. Cells were used for up to 4 passages in culture. 570 
 571 
Antibody-mediated EC activation. Monolayers of WT EC were stimulated with 1 μg/ml mouse–572 
anti-mouse H-2Ld/H-2Db (BD Biosciences 14-5999-85) or isotype control and 0.5 μg/ml goat–573 
anti-mouse IgG (BioLegend 405301) with and without coligation of CD31 molecules (rabbit–anti-574 
mouse CD31 5 μg/ml plus goat–anti-rabbit Ig 2.5 μg/ml). In addition, WT EC underwent MHC 575 
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class 1 molecule stimulation in the presence or absence of ICAM-1 ligation (rat–anti-mouse CD54 576 
(eBioscience 14-0549-82) 5 μg/ml plus goat anti-rat Ig 2.5 μg/ml (Biolegend 400202).  577 
 578 
Measurement of trans-endothelial electrical resistance (TEER) EC were grown on Transwell 579 
polycarbonate filters (pore size, 0.4 µm; Sigma-Aldrich, CLS3396) first coated with calfskin 580 
collagen type I (Sigma-Aldrich, C3867) and bovine plasma fibronectin (Sigma-Aldrich, F1141). 581 
Transendothelial resistance across the monolayer was determined by using an Endohmeter 582 
(World Precision Instruments, Sarasota, FL) stabilized at 148 ± 12 Ω. Resistance from coated 583 
cell-free inserts was always subtracted from the resistance obtained in the presence of 584 
endothelial cells.  585 
 586 
Actin cytoskeleton analysis. EC (105) were seeded onto each well of 24-well plates containing 587 
glass coverslips (VWR Internationa, P24G-1.0-10-F) coated with 100 μg of 2% gelatin (Sigma-588 
Aldrich, G9382). They were incubated overnight at 37°C with 5% CO2 in EC media to form a 589 
monolayer. EC monolayers were then fixed with 4% buffered paraformaldehyde (Sigma-Aldrich, 590 
16005) for 20 min at 4°C, washed three times with PBS and stained with 1 ng/ml tetramethyl 591 
rhodamine B isothiocyanate–conjugated phalloidin (Sigma-Aldrich, P1951) for 30 min at 37°C. 592 
Coverslips were extensively washed, air dried, and mounted in Vectorshield (Vector Laboratories, 593 
H-5000) mounting medium for fluorescence with DAPI (Vector Laboratories, H-1800) or Hoechst 594 
(Sigma, 94403) on glass slides. The slides were analyzed with wide-field fluorescence 595 
microscopy. 596 
ATP assay. ATP production by EC was measured using the ATP Assay Kit (Abcam, ab83355). 597 
106 WT and CD31 deficiency EC with or without treatments were harvested and homogenized, 598 
centrifuged to remove insoluble material, and the supernatant collected for use in subsequent 599 
steps according to the manufacturer's instructions. 600 
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Confocal microscopy. EC (105) were seeded onto each well of 24-well plates containing glass 601 
coverslips (VWR International, P24G-1.0-10-F) previously coated with 50ug/ml Polyl-D-lysin 602 
(Gibco, A3890401). They were incubated overnight at 37°C with 5% CO2 in EC media to form a 603 
monolayer. EC monolayers were then fixed with 4% buffered paraformaldehyde (Sigma-Aldrich, 604 
16005) for 20 min at 4°C, washed three times with PBS and stained with Glut 1 AF647 antibody 605 
(Novus Biological, NB110-39113), Aldolase 488 (Novus Biological, 42620AF488), Phalloidin 586 606 
(ThermoFisher Scientific A12380) antibodies for 4h at room temperature. Coverslips were 607 
extensively washed, air dried, and mounted in Vectorshield (Vector Laboratories, P24G-1.0-10-F) 608 
mounting medium for fluorescence with DAPI (Vector Laboratories, H-1800) or Hoechst (Sigma, 609 
94403) on glass slides. The slides were analyzed with a Zeiss LSM800 confocal microscope. 610 
 611 
Widefield deconvolution fluorescence microscopy. EC were cultured in DMEM medium and 612 
fixed with 3.7% formaldehyde. After fixing, they were stained with the antibodies indicated in the 613 
figures. Coverslips were extensively washed, air dried, and mounted in Vectorshield mounting 614 
medium for fluorescence with DAPI (Vector Laboratories, H-1800) on glass slides. Cells were 615 
visualized using a Zeiss Z1 fluorescence microscope (Carl Zeiss) equipped with an AxioCam 616 
MRm cooled monochrome digital camera and an ApoTome.2 imaging unit. Images were acquired 617 
using a Plan Apochromat 10×/0.8 NA objective. Standard epi-illuminating fluorescein and 618 
rhodamine fluorescence filter cubes were used, and 12-bit image datasets were generated using 619 
Axiovision software version 4.8. 620 
 621 
Quantitative real-time polymerase-chain reaction (qRT-PCR). Cells were harvested and 622 
stored in RNA-later (Qiagen, Crawley, UK) at –80°C until processing. RNA was purified using 623 
Trizol reagent according to the manufacturer’s instructions (Life Technologies) and assessed for 624 
quality and quantity using absorption measurements. Reverse transcription was performed 625 
according to the manufacturer’s instruction (Applied Biosystems). Gene expression analysis was 626 
done using SYBR Green Supermix (Biorad) in CFX connect light cycler (Biorad), according to the 627 
manufacturer’s instructions. Expression was calculated using the ∆∆ct method 78 and normalized 628 
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to a housekeeper gene (GAPDH). Primers for qPCR were designed with the help of online tools 629 
(Primer 3Plus) using at least one exon junction-binding site per primer pair. The sequences of the 630 
qPCR Primers are as follows: 631 
Glut-1 (5’-  CACTGTGGTGTCGCTGTTTG -3’ and  5’-ATGGAATAGGACCAGGGCCT -3’), VE-632 
cadherin (5’ - TCTTGCCAGCAAACTCTCCT - 3’ and 5’ - TTGGAATCAAATGCACATCG - 3’), c-633 
myc (5’ GCCCAGTGAGGATATCTGGA 3’ and 5’ ATCGCAGATGAAGCTCTGGT -3’), FoxO1 (5’ 634 
GTGAACACCATGCCTCACAC 3’ and 5’ CACAGTCCAAGCGCTCAATA 3’), c-myc (5’ 635 
GCCCAGTGAGGATATCTGGA 3’ and 5’ ATCGCAGATGAAGCTCTGGT -3’), mCPT-la (5’-636 
CCAAGTATCTGGCAGTCGA-3’and 5’–CGCCACAGGACACATAGT-3’), GAPDH (5′-637 
AGAACGGGAAGCTTGTCATCA-3′ and 5′-GACCTTGCCCACAGCCTTG-3′), Aldolase (5’- 638 
TGGACTAGAGGGACCTGGTG -3’ and 5’- GGGAGGGGGTAATATGGCTA -3’) .  639 
The thermal cycling profile for amplification was 95 °C for 10 min, followed by 40 cycles of 95 °C 640 
for 15 s and 54 °C for 1 min. Amplification was 95 °C for 10 min, followed by 40 cycles of 95 °C 641 
for 15 s and 60 °C for 1 min. To ensure the amplification specificity, the melting curve program 642 
was set as follows: 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s, right after the PCR cycles. 643 
The qPCR data were analyzed using the delta CT method by taking the CT values of the genes 644 
of interest from the house keeping gene following by normalization to the wildtype control sample. 645 
Cellular Fractionation and Isolation of Nuclei. Cells (5-10 x 106) were cultured in 60-mm 646 
diameter culture dishes until ∼80% confluency. For isolation of nuclear extracts, the cells were 647 
then collected into microtubes, centrifuged for 20 s in a microcentrifuge, and resuspended in 200 648 
μl of 10.0 mM Hepes (Gibco, 15630080), pH 7.9, containing 10.0 mM KCl, 1.5 mM MgCl2, and 649 
0.5 mM dithiothreitol. After incubation at 4 °C for 15 min, the cells were lysed by passing 10 times 650 
through a 22-gauge needle. Next, the cells were centrifuged for 20 seconds in a microcentrifuge, 651 
and the supernatant, cytoplasmic fraction was collected and frozen in small aliquots. The pellet, 652 
which contained the nuclei, was resuspended in 150 μl of 20 mM Hepes, pH 7.9, containing 20% 653 
v/v glycerol, 0.1 mM KCl, 0.2 mM EDTA (Invitrogen, AM9912), 0.5 mM dithiothreitol (Thermo 654 
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Scientific, A39255), and 0.5 mM phenylmethanesulfonyl fluoride (Sigma Aldrich,10837091001) 655 
and then stirred at 4 °C for 30 min. The nuclear extracts were then centrifuged for 20 min at 4 °C 656 
in a microcentrifuge. The supernatant was collected, aliquoted into small volumes, and stored at -657 
80 °C.  658 
Western Blotting. Nuclear or whole cell proteins derived from each cell sample were 659 
fractionated by SDS-PAGE, blotted onto a nitrocellulose membrane (Whatman, WHA10402506). 660 
Membranes were blocked for 2 hours at room temperature in 5% milk/TBS-Tween 20 and were 661 
incubated overnight at 4 °C with the primary antibodies listed in Reagents and Antibodies in the 662 
main text and subsequently with HRP-conjugated secondary antibody (1:5,000; Amersham 663 
Bioscience). Films then were scanned, and the intensity of the bands was quantified using 664 
ImageJ Software v.1.37c (NIH). 665 
Immunoprecipitation. Cells (107) were lysed in 1 mL lysis buffer [20 mM Tris⋅HCl (pH 8), 1% 666 
Triton X-100, 150 mM NaCl, 1 mM Na3VO4, 1 mM 4-benzenesulfonyl fluoride hydrochloride, 1 667 
μg/mL leupeptin]. After centrifugation, the lysate was precleared using Protein G-Sepharose 668 
(Sigma-Aldrich, P3296) for 30 min at 4 °C and then was incubated with specific antibodies for 1 h 669 
before the addition of Protein G-Sepharose and overnight incubation at 4 °C. Samples then were 670 
washed three times with lysis buffer, boiled in SDS/PAGE sample buffer, resolved using 10% 671 
SDS/PAGE, and analyzed by Western blotting. 672 
In-vitro 6NBDG uptake assay. Freshly isolated EC were washed in PBS and resuspended in 673 
glucose-free cell medium (Gibco, Cat11879-020) containing various mentioned 30 6-NBDG (Life 674 
Technologies, CatN23106) in glucose free cell medium was then added to the cells and the cells 675 
were further incubated for an additional 10-15 minutes. Finally, the cells were washed twice with 676 
warm PBS and resuspended in flow cytometry buffer and placed on ice. Immediate analysis was 677 
performed using flow cytometry to observe fluorescence uptake by the EC.  678 
 679 
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Measurement of ECAR and OCR. Real time bioenergetics analysis of extracellular acidification 680 
rates (ECAR) and oxygen consumption rates (OCR) of T-cells subjected to antibody stimulation 681 
was performed using the XF analyzer (Seahorse biosciences). T-cells were cultured in serum 682 
free, unbuffered XF assay medium (Seahorse biosciences, Cat 102365-100) for 1 hour. The cells 683 
were then seeded (6x105/well) into the seahorse XF24 cell plates for analysis. Perturbation 684 
profiling of the use of metabolic pathways by T-cells was achieved by the addition of oligomycin 685 
(1 μM), FCCP (1μM), Antimycin A (1μM), rotenone (1μM), D-glucose (10mM), 2-Deoxy-D-glucose 686 
(2DG, 50mM; all from Seahorse biosciences, Cat# 103020-100 and 103015-100). Experiments 687 
with the Seahorse system were done with the following assay conditions: 2 minutes mixture; 2 688 
minutes wait; and 4–5 minutes measurement. Metabolic parameters were calculated by Wave 689 
v2.4.1 Software. Experiments were done in at least triplicate wells. 690 
 691 
Mitochondrial oxidation of glucose, glutamine and fatty acid oxidation. Oxidation rates of 692 
glucose, glutamine and FAO were measured using an XFp Extracellular Flux Seahorse Analyzer 693 
(Seahorse Bioscience). WT and CD31 deficiency cells (15,000/well) were treated with MHC 694 
triggering for 45min prior to the start of the XFp Mito Fuel Flex Test kit, which was performed in 695 
accordance with manufacturer’s instructions. Each plotted value is the mean of at least 6 696 
replicates and is normalized to Hoechst signal in each well.  697 
 698 
Flow Cytometry. Cells were suspended in FACS buffer (PBS, 1% BSA, 0.01% sodium azide), 699 
stained with the appropriate concentration of fluorescence-conjugated antibodies, or isotype 700 
control antibodies, according to the manufacturer’s instructions, fixed in fix buffer (PBS, 4% 701 
paraformaldehyde, 1% FCS), and analyzed by a FACSAria cell sorter (Becton Dickinson). 702 
Acquired samples were analyzed using FlowJo 7.6 software (Tree Star, Inc.). 703 
 704 
Measurement of endothelial permeability in-vivo. Vascular permeability was quantitatively 705 
evaluated by extravasation of Evans blue as a marker of albumin extravasation (Belayev et al., 706 
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1996). Briefly, mice received anti-MHC and secondary cross-linking antibody (0.67μg and 707 
0.33μg/kg body weight, respectively) or anti-ICAM1 and secondary cross-linking antibody (3.35μg 708 
and 1.7μg/kg body weight, respectively) before Evans blue dye (2 mg/kg) i.v. injection. 45 min 709 
later. As indicated, some MHC-stimulated mice received either an Akt activator (administered i.p. 710 
at a dose of 7 mg/kg) or Metformin (i.p. 125 mg/kg) before administration of the antibodies. WT 711 
and cd31-/- mice from treatment and control groups were deeply anesthetized with chloral 712 
hydrate, and blood was obtained by cardiac puncture. After the mice were sacrificed, organs 713 
were collected, weighted and incubated in formamide (1 ml/100 mg) for 48 hours at 56°C to 714 
extract Evans blue. Absorbance at 600 nm was normalized by tissue weight, and by the relative 715 
concentration of Evans blue present in the blood of the corresponding mice. 716 
 717 
Skin grafting. Skin grafting was conducted using a method previously described by Billingham 718 
and Medawar 79 using tail skin grafted onto the lateral thorax. Briefly, donor tail skin was 719 
removed and cut into 1cm2 sections. A piece of skin was removed from the right flank of 720 
anesthetized recipient mice to create a graft bed and a 1 cm2 piece of tail skin was placed in 721 
the graft bed. The graft was covered with muslin and a plaster cast was then wrapped around 722 
the midriff and graft. Plasters were removed 7-10 days after grafting and grafts were inspected 723 
every other day.  724 
 725 
Electron Microscopy of Resin-Embedded Cells. For high-pressure freezing suspension, 726 
cultured endothelial cells were harvested by filtering and immediately frozen in a high-pressure 727 
freezing apparatus (HPF010; Bal-Tec, Balzers, Liechtenstein). For subsequent freeze 728 
substitution, the material was kept at −85°C for 60 h before slowly being warmed to 0°C for a 729 
period of 18 h. Substitution was performed in an AFS freeze substitution unit (Leica, Bensheim, 730 
Germany).  The sections were poststained with aqueous uranyl acetate/lead citrate, and images 731 
were captured with a Hitachi H7650 transmission electron microscope (Hitachi High-732 
Technologies) operating at 80 kV. 733 
 734 
 30
Statistical analysis. Data was statistically analyzed using Prism 5.03 software (GraphPad). The 735 
statistical tests used are indicated in the corresponding Figure legends. 736 
 737 
Data availability 738 
All data supporting the results presented herein are available from the corresponding authors 739 
upon reasonable request. The source data for all the graphs and un-cropped gels and blots in the 740 
main Figures and Supplementary Information are provided as a Source Data file.are provided as 741 
a Source Data file.  742 
 743 
 744 
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FIGURE LEGENDS 985 
 986 
Figure 1. CD31 interactions promote the recovery of endothelial integrity following 987 
endothelial contraction induced by MHC molecule triggering.  988 
a-d: Following MHC or ICAM-1 and/or CD31 antibody-mediated co-ligation for 30 minutes, EC 989 
were fixed and stained with rhodamine-phalloidin. Images taken on EC monolayers seeded at 990 
identical density are shown in panels a-b. The average F-actin intensity per cell of three 991 
independent experiments is shown in panels c and d. Scale bar, 20 μm. (n=3 biologically 992 
independent samples, N=3 independent experiments, data are mean ± SD). One-way Anova with 993 
Tuckey post-hoc test. MHC vs all ****p<0.0001, MHC+CD31 vs Isc ****p<0.0001 , MHC+CD31 vs 994 
all ****p <0.0001 995 
e: Western blot (WB) analysis of Erk activation by WT and cd31-/- EC 30 minutes after MHC 996 
stimulation. The bar graph shows relative protein expression ± SEM. N=3 independent 997 
experiments (data are mean ± SD). One-way Anova with Tuckey post-hoc test. cd31-/- MHC vs 998 
cd31-/- IsC ***p=0.0002 , cd31-/- MHC vs all ****p<0.0001 999 
f: Western blot (WB) analysis of RhoA activation by WT and cd31-/- EC 30 minutes after MHC 1000 
stimulation. The bar graph shows relative protein expression ± SEM. N=3 independent 1001 
experiments (data are mean ± SD).  One-way Anova with Tuckey post-hoc test. cd31-/- 15’ vs all 1002 
***p=0.0003 , cd31-/- 30’ vs all ****p<0.0001 1003 
g: Immunoprecipitation of CD31 molecules from WT EC exposed to MHC/ICAM-1 stimulation for 1004 
30 min followed by immunoblotting with an anti-phosphotyrosine antibody and an anti-SHP2 1005 
antibody. The bar graph shows relative protein expression ± SEM. N=3 independent experiments. 1006 
One-way Anova with Tuckey post-hoc test. pTyr20 MHC vs all ****p<0.0001 , SHP2 MHC vs all 1007 
****p <0.0001 , pTyr20 ICAM-1 vs all **** p<0.0001 1008 
h: WT or cd31−/− mice (n=6 mice, N=2 independent experiments) received anti-MHC and 1009 
secondary cross-linking antibody (0.67μg and 0.33μg/kg body weight, respectively) in saline 1010 
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solution i.v.. After 3 or 6 hours, 100 μL of 2% Evans blue in saline solution was injected. Dye was 1011 
allowed to circulate for 45 min before organs dye content was assessed spectrophotometrically 1012 
and normalized to plasma levels (data are mean ± SEM). One-way Anova with Tuckey post-hoc 1013 
test. Lung cd31-/- vs WT *p=0.0352 , heart cd31-/- vs WT **p=0.0045 , kidney cd31-/- vs WT 1014 
***p=0.0009 , liver cd31-/- vs WT **p=0.0071 , spleen cd31-/- vs WT ** p=0.002 1015 
i: H-2B-specific alloreactive T-cells were obtained by stimulation of Balb/C mice-derived 1016 
splenocytes (H2-D) with sublethally irradiated WT splenocytes in the presence of 20U/ml IL-2. T-1017 
cells were harvested 72 hours after stimulation and seeded (105/well) onto confluent WT or cd31-/- 1018 
EC monolayers grown on 0.2 μm-pore transwells and previously treated with IFN-γ for 48 hours 1019 
to upregulate MHC expression. TEER was measured as described in the Methods section. n=3 1020 
biologically independent samples, N=2 independent experiments. (data are mean ± SD) One-way 1021 
Anova with Tuckey post-hoc test. 3 hours WT vs cd31-/- ****p<0.0001 , 6 hours WT vs cd31-/- 1022 
****p<0.0001 , 24 hours WT vs cd31-/- ***p=0.0005 1023 
j: WT or cd31−/− mice (n=6 mice, N=2 independent experiments) were treated either with saline 1024 
solution or with IFN-γ i.p. (70,000 U/mouse) i.p.. After 48 hours, some mice received an i.v. 1025 
injection of the SEA superantigen (60 ng/mouse). After a further 4 hours, 100 μL of 2% Evans 1026 
blue in saline solution was injected. Dye was allowed to circulate for 45 min before organs dye 1027 
content was assessed spectrophotometrically and normalized to plasma levels (data are mean ± 1028 
SEM). One-way Anova with Tuckey post-hoc test. lung cd31-/- SEA vs WT SEA ***p=0.0006 , lung 1029 
cd31-/- SEA vs cd31-/- PBS **p=0.002 , liver cd31-/- SEA vs WT SEA **p=0.00124 , liver cd31-/- SEA 1030 
vs cd31-/- PBS **=0.004 , heart cd31-/- SEA vs WT SEA ***p=0.0007 , heart cd31-/- SEA vs cd31-/- 1031 
PBS ** p=0.0088 ,  spleen cd31-/- SEA vs WT SEA ****p<0.0001 , spleen cd31-/- SEA vs cd31-/- 1032 
***p=0.0002 , kidney spleen cd31-/- SEA vs WT SEA ****p<0.0001 , kidney cd31-/- SEA vs cd31-/- 1033 
***p=0.0008 .  1034 
.  1035 
 1036 
 40
Figure 2. CD31 signals prevent VE-cadherin and β-catenin phosphorylation in response to 1037 
MHC stimulation via ITIM 686-thyrosine phosphorylation.  1038 
a: phosphorylation of β-catenin (Y654) by MHC- or ICAM-1-stimulated (30 minutes) WT or cd31-/- 1039 
EC was analysed by western blotting. The bar graph shows relative protein expression ± SEM. 1040 
(N=3 independent experiments). One-way Anova with Tuckey post-hoc test. cd31-/- MHC vs all *** 1041 
p= 0.0002 1042 
b-e: phosphorylation of β-catenin (Y654, b) or VE-cadherin (Y685, d) by MHC-stimulated (30 1043 
minutes) WT or CD31-/- EC was analysed by widefield fluorescence microscopy. The bar graphs 1044 
(c, e) show the mean fluorescence intensity/per cell of the indicated marker measured in three 1045 
independent experiments by ImageJ software. Scale bar, 20 μm. Magnification ×20. Data are 1046 
mean ± SD. One-way Anova with Tuckey post-hoc test. (c) cd31-/- MHC vs all ****p<0.0001; (e) 1047 
cd31-/- MHC vs all ****p<0.0001 1048 
f-g: CD31 gene constructs with mutations leading to the loss-of-function amino acid substitutions 1049 
Y663F and Y686F in the ITIMs were generated and expressed by lentiviral transduction into 1050 
cd31-/- (KO) ECs (KOCD31Y686F, KOCD31Y663F). As a control, CD31 KO ECs were transduced with a 1051 
wild-type CD31 gene construct (KOCD31WT) or an empty plasmid (KOpklo.1). ECs (6 × 104/well) 1052 
previously treated with 300 U/ml IFN-γ for 48 hours (to enhance MHC molecule and ICAM-1 1053 
expression) were seeded onto 0.2 μm-pore transwells and stimulated with 5 μg/ml anti-mouse H-1054 
2Ld/H-2Db, or relevant isotype control followed by a secondary cross-linking Ab. TEER was 1055 
measured as described in the Methods section. n=3 biologically independent samples, N=2 1056 
independent experiments. Data are mean ± SD. One-way Anova with Tuckey post-hoc test. (f) 1057 
KO CD31WT vs all ***p= 0.0002; (g) KO CD31WT vs all ***p=0.0002, KOY663 vs. KO pklo.1 **p=0.0024 1058 
 1059 
Figure 3. CD31 regulates EBF via its effects on EC metabolism.  1060 
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(a) EC were pre-treated with the glucose analogue 2-DG (5 mM, 2 hours) then MHC-1- or 1061 
ICAM--stimulated for 4 hours prior to TEER measurements. The bar graph shows the mean of 1062 
measurement collected in 3 separate experiments of identical design ± SD. One-way Anova 1063 
with Tuckey post-hoc test. 2DG MHC vs all ***p=0.0003 (b) Glut-1 expression by EC following 1064 
MHC stimulation (2 hours) was evaluated by qRT-PCR. Data are mean ± SD. Two-tailed 1065 
Student’s T test. MHC vs IsC *p=0.0412 (c-d) Representative histograms of antibody-1066 
stimulated WT or CD31-deficient EC incubated with 6-NBDG for 2 hours prior to analysis. 2-1067 
DG was used as a negative control. The graph shows the mean MFI measured in 3 1068 
independent experiments ± SD. One-way Anova with Tuckey post-hoc test.  WT IsC vs WT 1069 
MHC **p=0.003 , cd31-/- IsC vs cd31-/- MHC ns= 0.058 (e) ATP levels were measured in WT and 1070 
CD31-deficient EC 4 hours after MHC or insulin (1.8µM) stimulation.   Data are mean ± SD. 1071 
Two-tailed Student’s T test. WT MHC vs cd31-/- MHC ***p=0.0002 , WT insulin vs cd31-/- insulin 1072 
**p=0.0062 1073 
Extracellular acidification rate (ECAR) of unstimulated and antibody-stimulated WT and CD31-1074 
deficient EC is shown in panel f-h. The basal and maximal glycolysis and the glycolytic reserve 1075 
are shown in panel i-k. Wells were first injected with anti MHC antibodies at the indicated time 1076 
point. Isotype-matched and secondary antibodies were used as controls. Further injections 1077 
followed at the time point indicated (arrows) introducing the indicated compounds into the wells.  1078 
N=3 independent experiments. The error bars represent SD. One-way Anova with Tuckey 1079 
post-hoc test. (f) WT time 81 vs cd31-/- time 81 **p=0.0023 , WT time 94 vs cd31-/- time 94 1080 
***p=0.0017; (h) IsC Glu/Oligo injection vs MHC Glu/Oligo **p=0.012 , IsC Oligo/2DG vs MHC 1081 
Oligo/2DG *p=0.027; (i) WT MHC vs WT IsC ****p<0.0001 , WT IsC vs cd31-/- IsC/MHC *p=0.0245 , 1082 
WT MHC vs cd31-/- IsC/MHC ****p<0.0001; (j) WT IsC vs cd31-/- IsC **p=0.0056 , WT IsC vs cd31-/- 1083 
MHC **p=0.0097 ,  WT MHC vs cd31-/- IsC **p=0.0024 , WT MHC vs cd31-/- MHC **p=0.0041; (k) WT 1084 
IsC vs cd31-/- IsC ***p=0.0002 , WT IsC vs cd31-/- MHC ***p=0.0003 ,  WT MHC vs cd31-/- IsC 1085 
***p=0.00024 , WT MHC vs cd31-/- MHC ***p=0.00021 ,  1086 
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 1087 
Figure 4. CD31-deficient EC increase mitochondrial respiration upon MHC stimulation.  1088 
Oxygen consumption rate (OCR), basal, maximal respiration and spare capacity of unstimulated 1089 
WT and CD31-deficient EC is shown in panels a and b, respectively (N=3 independent 1090 
experiments). The error bars represent SD. One-way Anova with Tuckey post-hoc test.  Basal 1091 
respiration WT vs cd31-/- ****p<0.0001 , Max respiration WT vs cd31-/- ****p<0.0001 , Spare 1092 
capacity WT vs cd31-/- ****p<0.0001 1093 
Oxygen consumption rate (OCR) of unstimulated and MHC-stimulated WT and cd31-/- EC is 1094 
shown in panels c and d, respectively. The maximal respiration and spare capacity are shown in 1095 
the right-had-side of each panel. Wells were first injected with anti MHC antibodies at the 1096 
indicated time point. Isotype matched and secondary antibodies were used as controls. Further 1097 
injections followed at the time point indicated (arrows) introducing the indicated compounds into 1098 
the wells. N=3 independent experiments. The error bars represent SD. One-way Anova with 1099 
Tuckey post-hoc test. d Rotenone injection IsC vs Rotenone injection MHC *p=0.04 , Max 1100 
respiration IsC vs MHC **p=0.002 , Spare capacity IsC vs MHC *p=0.0327 1101 
(e) EM analysis of EC mitochondria and mitochondrial cristae of WT and cd31-/- EC MHC- or 1102 
IsC-stimulated over 4 hours. Scale bar = 500nm, represents 2 experiments. The mean transverse 1103 
diameter and number of mitochondria measured in 15 images from each experimental group is 1104 
shown in panel f and g, respectively. In panel h, maximum cristae width was measured from 15 1105 
images from each experimental group using ImageJ software and it is expressed in arbitrary 1106 
units, Bar graphs depicts mean ± SEM (N=3 independent experiments). One-way Anova with 1107 
Tuckey post-hoc test. (f) cd31-/- MHC vs all ****p<0.0001; (g) cd31-/- MHC vs all **p= 0.003; (h) 1108 
cd31-/- MHC vs all *p= 0.019 1109 
(i) MitoTracker Green staining of WT and cd31-/- EC MHC- or IsC-stimulated for 4 hours was 1110 
analyzed by flow cytometry. Representative histograms from 2 replicate experiments are 1111 
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shown. (j) In similar experiments, MitoTracker Red fluorescence was measured from 15 1112 
images from each experimental group using ImageJ software, Bar graphs depicts mean ± 1113 
SEM (N=3 independent experiments). One-way Anova with Tuckey post-hoc test. WT IsC vs 1114 
WT MHC ****p<0.0001 , WT IsC vs cd31-/- IsC ****p<0.0001 ,  WT IsC vs cd31-/- MHC ****p<0.0001 , 1115 
WT MHC vs cd31-/- IsC ****p<0.0001 ,  WT MHC vs cd31-/- MHC ****p<0.0001, cd31-/- IsC vs cd31-/- 1116 
MHC ***p=0.0002 1117 
 1118 
Figure 5. The metabolic response to endothelial barrier breach is src-phosphatase-1119 
dependent.  1120 
Confluent EC monolayers were MHC-stimulated and treated with the selective SHP1/2 inhibitor 1121 
(50 μM for 3 hours) or vehicle as a control. (a) The bar graph shows the mean TEER values 1122 
measured in 3 independent experiments. (b) Percentage of EC viability following treatment with 1123 
SHP1/2 inhibitor determined by the trypan blue exclusion assay in 3 independent experiments. 1124 
(c-f) ECAR measured in WT (c-d) or cd31-/- EC (e-f) following MHC antibody-stimulation with or 1125 
without pre-treatment with the SHP1/2 inhibitor (50μM for 45 min). Basal and maximal glycolysis 1126 
and glycolytic reserve are shown in panels d and f. (g-j) OCR measured in WT (g-h) or CD31-1127 
deficient EC (i-j) following MHC antibody-stimulation with or without pre-treatment with the 1128 
SHP1/2 inhibitor. Basal and maximal respiration and spare capacity are shown in panels i and j. 1129 
(N=3 independent experiments). Data are shown as mean ± SEM; significant differences were 1130 
determined using one-way Anova with Tuckey post-hoc test.   1131 
(a) IsC vehicle vs MHC vehicle ****p<0.0001 , MHC vehicle vs MHC+SHP inhibitor ****p<0.0001; 1132 
(c) Glu/Oligo injection WT MHC vs all ****p<0.0001 , Oligo/2DG injection WT MHC vs all 1133 
*p=0.0103; (d) Basal glycolysis WT IsC vs WT MHC **p=0.0039 , Basal glycolysis WT MHC vs 1134 
WT+SHP inhibitor *p=0.047 , Glycolytic reserve WT MHC VS WT+SHP inhibitor *p=0.0482 , Max 1135 
glycolysis WT IsC vs WT MHC ***p=0.0008 , Max glycolysis WT MHC VS WT+SHP inhibitor 1136 
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**p=0.0015; (e) Glu/Oligo/2DG injection cd31-/- MHC+SHP Inhibitor vs all ****p<0.0001; (f) Basal 1137 
glycolysis cd31-/- MHC vs cd31-/- MHC+SHP inhibitor **p=0.019 , Glycolysis reserve  cd31-/- MHC 1138 
vs cd31-/- MHC+SHP inhibitor ***p=0.0003 , Max glycolysis cd31-/- MHC vs cd31-/- MHC+SHP 1139 
inhibitor *0.0384; (i) FCCP/Rotenone injection cd31-/- MHC+SHP inhibitor vs all ****p<0.0001 ,  1140 
FCCP/Rotenone injection cd31-/- Isc vs cd31-/- IsC+SHP inhibitor ***p=0.0006; (j) Max respiration 1141 
cd31-/- IsC vs cd31-/- MHC *p=0.0177 , Max respiration cd31-/- IsC vs cd31-/- MHC+SHP inhibitor 1142 
***p=0.0004 , Spare capacity cd31-/- IsC vs cd31-/- MHC ****p<0.0001 , cd31-/- IsC vs cd31-/- 1143 
MHC+SHP inhibitor ****p<0.0001 1144 
Figure 6. CD31 signals induce transcription of glycolytic enzymes via inhibition of FoxO1 1145 
activity.   1146 
WT and cd31-/- EC were stimulated by MHC antibody-ligation or treated with an Isotype-Matched 1147 
Control and secondary antibody (4 hours). (a-b) Expression of the indicated enzymes was 1148 
analyzed by immunoblotting and quantified by densitometry. N=3 independent experiments. (c) 1149 
Expression of aldolase A mRNA in WT and CD31 deficient EC was determined by RT-PCR 2 1150 
hours after stimulation.  N=3 independent experiments. Data are mean ± SD. One-way Anova 1151 
with Tuckey post-hoc test. (b) PFKFB3 WT IsC vs WT MHC ****p<0.0001 , PFKFB3 WT IsC vs 1152 
cd31-/- MHC ****p<0.0001 , PFKFB3 WT MHC vs cd31-/- MHC ****p<0.0001 , Enolase2 WT IsC 1153 
vs WT MHC ****p<0.0001 , Enolase2 cd31-/- IsC vs cd31-/- MHC ****p<0.0001 , Enolase1 WT 1154 
IsC vs WT MHC **p<0.009 , Enolase1 cd31-/- IsC vs cd31-/- MHC **p<0.003 , Aldolase WT MHC 1155 
vs all ****<0.0001 ,PGAM1 WT IsC vs WT MHC **p=0.007 , PGAM1 cd31-/- IsC vs cd31-/- MHC 1156 
**p=0.0051 (c) WT MHC vs all **p=0.001 1157 
(d) Phosphorylation of Akt (ser473) in WT and cd31-/- EC was measured 30 minutes after MHC 1158 
molecule triggering. WT EC were also exposed to the SHP1/2 inhibitor during stimulation. The 1159 
bar graph shows the nucleus/cytoplasm ration of protein quantified by densitometry. N=3 1160 
independent experiments. Data are mean ± SD. One-way Anova with Tuckey post-hoc test. WT 1161 
IsC vs WT MHC ****p<0.0001 , WT MHC vs WT MHC+SHP inhibitor ****p<0.0001 ,WT MHC vs 1162 
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cd31-/- IsC **p=0.0024 , WT MHC vs cd31-/- MHC **p=0.002 1163 
 (e) 2 hours after stimulation EC were stained using rabbit anti-mouse FoxO1 (green) and DAPI 1164 
(blue). The nuclear distance between MHC-stimulated cd31-/- ECs reflects endothelial 1165 
contraction, as experiments were performed starting from identical EC monolayers. Scale bar = 1166 
20 μm.  N=3 independent experiments. (f) For quantification, 500 cells per coverslip were 1167 
analyzed, and the bar graph shows the percentage of cells displaying nuclear FoxO1 localization 1168 
measured in three independent experiments ± SD. one-way Anova with Tuckey post-hoc test. 1169 
cd31-/- IsC vs cd31-/- MHC ****p<0.0001 1170 
 (g) cMyc protein expression in WT and cd31-/- EC was measured 2 hours after MHC molecule 1171 
triggering.  WT EC were also exposed to the SHP1/2 inhibitor during stimulation. The bar graph 1172 
shows protein quantification by densitometry in three independent experiments ± SD. One-way 1173 
Anova with Tuckey post-hoc test. WT IsC vs WT MHC ***p=0.0002 , WT MHC VS WT 1174 
MHC+SHP inhibitor **p=0.0034 , WT MHC vs cd31-/- IsC ***p=0.00023 , WT MHC vs cd31-/- MHC 1175 
***p=0.0002 1176 
 (h) Following antibody stimulation for 2 hours nuclear fractions were isolated from EC, and 1177 
subjected to anti-FoxO1 immunoblot assay. The bar graph shows protein quantification by 1178 
densitometry in three independent experiments ± SEM. One-way Anova with Tuckey post-hoc 1179 
test. WT MHC vs all **p=0.0023 , WT MHC+SHP inhibitor vs all ***p=0.0009 , cd31-/- vs all 1180 
**p=0.007 1181 
WT EC were also exposed to the SHP1/2 inhibitor and CD31-deficient EC were pre-treated with 1182 
an Akt activator (500nM) for 3 hours before stimulation (N=2). In similar experiments, isolated 1183 
nuclei were stained with anti-Foxo1 antibody and analysed by flow cytometry. Representative 1184 
histograms and a summary of five independent experiments are shown in panel i and j, 1185 
respectively. (k) cMyc mRNA levels in the EC stimulated with anti-MHC or control antibodies for 2 1186 
hours and treated with the indicated compounds were measured by RT-PCR. N=3 independent 1187 
experiments. Data are mean ± SD. one-way Anova with Tuckey post-hoc test. (j) WT IsC+AKT 1188 
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activator vs all **p=0.002 , cd31-/- vs all **p=0.006 (k) WT IsC vs WT MHC *p=0.044 , WT MHC 1189 
vs WT MHC+SHP inhibitor *p=0.047 , cd31-/- IsC vs cd31-/- MHC **p=0.0065 ,  cd31-/- MHC vs 1190 
cd31-/- MHC+Akt activator *p=0.043 1191 
Figure 7. CD31 signalling promotes β-catenin nuclear translocation and upregulates cMyc 1192 
expression. 1193 
WT and cd31-/- EC monolayers were stimulated by MHC antibody-ligation or treated with an 1194 
Isotype-matched control and secondary antibodies (2 hours). Some cd31-/- ECs were also 1195 
treated with an Akt activator (500 nM, 3 hours) prior to antibody stimulation. Vehicle was added in 1196 
the untreated cultures (IsC and MHC ligation). (a) β-catenin and cMyc expression were 1197 
determined by immunofluorescent antibody staining and wide-field microscopy. The nucleus was 1198 
stained with DAPI. The mean fluorescence intensity of cMyc and β-catenin measured in 500 cells 1199 
in three independent experiments is shown in panel b and c respectively.  Scale bar = 40 μm. 1200 
Data are mean ± SD. one-way Anova with Tuckey post-hoc test. (b) WT IsC vs WT MHC; (c) WT 1201 
IsC vs WT MHC ***p=0.0008 , cd31-/- IsC+C991 vs cd31-/- MHC+C991 ***p=0.0002 1202 
d-e: cMyc (d) and aldolase (e) gene transcription by WT (upper panels) and cd31-/- (lower panels) 1203 
EC at the indicated time points. n=3 biologically independent samples, N=2 independent 1204 
experiments. Error bars represent SD. One-way Anova with Tuckey post-hoc test or T-test (d-e). 1205 
(d) WT IsC 30’ vs WT MHC 30’ **p=0.003 , WT IsC 120’ vs WT MHC 120’ ****p<0.0001; (e) WT 1206 
IsC 30’ vs WT MHC 30’ ***p=0.0008 , WT IsC 120’ vs WT MHC 120’ ****p<0.0001 , WT IsC 240’ 1207 
vs WT MHC 240’ ****p<0.0001  1208 
 1209 
Figure 8. Akt and AMPK activation restore the glycolytic response in CD31-deficient EC in-1210 
vitro and in-vivo. cd31-/- EC were treated with an Akt activator (500 nM, 3 hours, a) or Metformin 1211 
(5mM, 3 hours, b), prior to MHC-stimulation and glycolytic flux measurement N=3 independent 1212 
experiments. Error bars represent SD. One-way Anova with Tuckey post-hoc test. (a) Glu/Oligo 1213 
injection MHC+Akt activator vs all *p=0.04 , Oligo/2DG injection MHC+Akt activator vs IsC 1214 
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*p=0.048; (b) Glu/Oligo injection MHC+Metformin vs all **p=0.003 ,  Oligo/2DG injection 1215 
MHC+Metformin vs all *p=0.05 1216 
(c-d) cd31-/- EC were immunostained 2 hours after MHC-stimulation by rabbit anti-mouse FoxO1 1217 
(green) and DAPI (blue). In some cultures, metformin was added. 500/coverslip were analysed. 1218 
(d) Percentage of cells displaying nuclear FoxO1 localization (N=3 independent experiments). 1219 
Scale bar = 20 μm. (e) Quantitative analysis of TEER of cd31-/- EC treated as indicated 3 hours 1220 
after stimulation. (f) CD31−/− mice (n=5 mice, N=2 independent experiments) received anti-MHC 1221 
and secondary cross-linking antibody (0.67μg and 0.33μg/kg body weight, respectively) or an 1222 
Isotype-matched control antibody (IsC) and secondary cross-linking antibody (3.35μg and 1223 
1.7μg/kg body weight, respectively) i.v.. Some mice received either an Akt activator (i.p., 7 mg/kg) 1224 
or Metformin (i.p., 125 mg/kg). After 6 hours, Evans blue dye (2 mg/kg) was administered by i.v. 1225 
and organ dye (n=3 mice; N=2 independent experiments). Error bars represent SD. One-way 1226 
Anova with Tuckey post-hoc test. (d) IsC vs MHC ****p<0.0001 , MHC vs MHC+Metformin 1227 
***p=0.0004; (e) IsC vs MHC ****p<0.0001 , MHC vs MHC+Metformin ****p<0.0001; (f) lung IsC 1228 
vs MHC ****p<0.0001 , lung MHC vs MHC+Akt activator ***p=0.0002 , lung MHC vs 1229 
MHC+Metformin ***p=0.00021 , heart IsC vs MHC ***p=0.0008 , heart MHC vs MHC+Akt 1230 
activator ****p<0.0001 , heart MHC vs MHC+Metformin ***p=0.00019 , kidney IsC vs MHC 1231 
***p=0.000193 , kidney MHC vs MHC+Akt activator ***p=0.000183 , kidney MHC vs 1232 
MHC+Metformin ***p=0.000173 , liver IsC vs MHC ***p=0.0009 , liver MHC vs MHC+Akt activator 1233 
***p=0.00091 , liver MHC vs MHC+Metformin ***p=0.00049 , spleen IsC vs MHC ***p=0.00017 , 1234 
spleen MHC vs MHC+Akt activator ***p=0.00016 , spleen MHC vs MHC+Metformin ***p=0.00027. 1235 
g-h: 991 AMPK-activator-treated cd31-/- EC were 500 nM, 3 hours), underwent MHC-stimulation 1236 
and glycolytic flux measurement (g). h: Basal glycolysis, glycolytic reserve and max glycolysis (i) 1237 
TEER of CD31-deficient EC treated as indicated 3 hours after MHC-stimulation with or without 1238 
the AMPK-selective activator 991 (500 nM). N=3 independent experiments. (j) CD31−/− mice (n = 1239 
5 N=2) received anti-MHC and cross-linking antibody (0.67μg and 0.33μg/kg, respectively) or an 1240 
IsC and cross-linking antibody (3.35μg and 1.7μg/kg, respectively) i.v.. Some mice received 1241 
AMPK-activator C991 (i.p. 7 mg/kg). After 6 hours, vascular leakage was measured as above. 1242 
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(n=3 mice, N=2 independent experiments) Error bars represent SEM. One-way Anova with 1243 
Tuckey post-hoc test. (g) Glu/Oligo injection MHC+C991 vs all ***p=0.0002 , Oligo/2DG 1244 
MHC+C991 vs all **p=0.0024; (h) Basal Glycolysis MHC+C991 vs all ***p=0.0002, Max 1245 
glycolysis MHC+C991 vs all ****p< 0.0001; (i) IsC vs MHC ****p<0.0001 , MHC vs IsC+C991 1246 
****p<0.0001 , MHC vs MHC+C991 ****p<0.0001; (j) lung IsC vs MHC *p=0.0309 , lung MHC vs 1247 
MHC+C991 *p=0.041 , heart IsC vs MHC **p=0.0041 , heart MHC vs MHC+C991 **p=0.0058, 1248 
kidney IsC vs MHC *p=0.0205 , kidney MHC vs MHC+C991 *p=0.0338 , liver IsC vs MHC 1249 
**p=0.0019 , liver MHC vs MHC+C991 *p=0.0088 , spleen IsC vs MHC **p=0.0029 , spleen MHC 1250 
vs MHC+C991 ***p=0.0009. 1251 
k-l: WT female mice received WT (blue symbols) or cd31-/- (black symbols), male or female-1252 
derived skin grafts. Some recipients were treated with Metformin (+ Met, i.p. 125 mg/kg daily), or 1253 
vehicle alone. Two weeks later skin graft vascular leakage was measured as above, normalized 1254 
to non-grafted skin l: Representative HE-stained sections of grafts harvested 2 weeks after 1255 
transplantation. Arrows indicate eosinophilic (protein-rich) edema. (n=3 mice, N=2 independent 1256 
experiments). Error bars represent SEM. Error bars represent SD. One-way Anova with Tuckey 1257 
post-hoc test. ♂ WT♀ WT vs ♂cd31-/- ♀WT *p=0.032 , ♂cd31-/- ♀WT vs ♂cd31-/- ♀WT+Met 1258 
**p=0.0098 1259 
 1260 
Figure 9. A model for the CD31-induced barrier response. MHC triggering induces RhoA and 1261 
Erk activation and EC contraction (1). Erk phosphorylation is modulated by CD31 signals, 1262 
possibly via SHP-2 (2). MHC signals induce CD31 ITIM phosphorylation and SHP-2 recruitment. 1263 
SHP-2 prevents the phosphorylation of b-catenin (5) and VE-cadherin (6), thus stabilizing the 1264 
junctional complex. In addition, dephosphorylated b-catenin can transfer to the nucleus where it 1265 
induces cMyc transcription. In parallel, SHP-2 induces AKT activation which in turn inhibits 1266 
FoxO1 nuclear translocation, thus preventing inhibition of cMyc transcription. This leads to 1267 
enhanced transcription of glycolysis enzymes and enhanced glycolysis required for actin 1268 
remodelling and maintenance of junctional anchorage. 1269 
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